Denali Therapeutics, Inc. (DNLI)
20.57
-0.14
(-0.68%)
USD |
NASDAQ |
Apr 17, 16:00
20.57
0.00 (0.00%)
Pre-Market: 08:28
Denali Therapeutics SG&A Expense (Quarterly) : 39.46M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Neurocrine Biosciences, Inc. | 301.80M |
| Protalix Biotherapeutics, Inc. | 3.526M |
| Biogen, Inc. | 682.50M |
| Agenus, Inc. | 12.30M |
| Curis, Inc. | 2.883M |